HLA Class I Antigen Processing Machinery Component Expression and Intratumoral T-Cell Infiltrate as Independent Prognostic Markers in Ovarian Carcinoma

Purpose: Defects in the antigen processing machinery (APM) may provide tumor cells with a mechanism to escape immune recognition. The purpose of this study is to determine the clinical significance of APM component down-regulation and tumor-infiltrating T cells in ovarian carcinoma. Experimental Design: After institutional review board approval, tumor samples from 150 patients with invasive epithelial ovarian cancers were examined for TAP1, TAP2, tapasin, HLA class I heavy chain (HLA-HC), β2 microglobulin, and T-cell (CD3+ and CD8+) tumor infiltration using immunohistochemistry. Results: The majority of tumors had either heterogeneous or positive expression of TAP1, TAP2, HLA-HC, and β2 microglobulin (66.7%, 73.3%, 70.7%, and 63.3%, respectively), except tapasin for which 58% of the tumors lacked expression. Furthermore, 67% and 88% of the lesions possessed intratumoral and peritumoral CD3+ or CD8+ cells, respectively. The majority of APM component expression examined was significantly associated with both intratumoral and peritumoral T-cell infiltration (P < 0.05). The expression of APM components and the presence of intratumoral T-cell infiltrates were significantly associated with improved survival (all P ≤ 0.01); however, peritumoral T-cell infiltrates did not significantly affect survival (P = 0.33). APM component down-regulation (P < 0.001), lack of intratumoral T-cell infiltrates (P = 0.03), and suboptimal cytoreduction (P < 0.001) were independent prognostic markers for death from ovarian carcinoma. Conclusion: The negative effect of APM component down-regulation by itself and in combination with absent intratumoral T-cell infiltration on the survival of patients with ovarian carcinoma implies a role for immune escape in addition to immunosurveillance in the clinical course of disease.

[1]  S. Ferrone,et al.  HLA class I antigen loss, tumor immune escape and immune selection. , 2002, Vaccine.

[2]  G. Pawelec.  Tumour escape: antitumour effectors too much of a good thing? , 2004, Cancer Immunology, Immunotherapy.

[3]  D. Templeton,et al.  Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis. , 1999, Journal of immunology.

[4]  Z. Trajanoski,et al.  Effector memory T cells, early metastasis, and survival in colorectal cancer. , 2005, The New England journal of medicine.

[5]  S. Ferrone,et al.  HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. , 2006, Cancer research.

[6]  Anil K Sood,et al.  Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  S. Ferrone,et al.  HLA class I antigen expression in malignant cells: why does it not always correlate with CTL-mediated lysis? , 2004, Current opinion in immunology.

[8]  F. Marincola,et al.  Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. , 2000, Advances in immunology.

[9]  George Coukos,et al.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.

[10]  R. Mariuzza,et al.  The structure of the T cell antigen receptor. , 1996, Annual review of immunology.

[11]  R. Steinman,et al.  Immunotherapy: Bewitched, Bothered, and Bewildered No More , 2004, Science.

[12]  S. Ferrone,et al.  Human Leukocyte Antigen and Antigen Processing Machinery Component Defects in Astrocytic Tumors , 2005, Clinical Cancer Research.

[13]  Soldano Ferrone,et al.  Tumors as elusive targets of T-cell-based active immunotherapy. , 2003, Trends in immunology.

[14]  S. Ferrone,et al.  Endoplasmic reticulum chaperone-specific monoclonal antibodies for flow cytometry and immunohistochemical staining. , 2003, Tissue antigens.

[15]  K. Garcia,et al.  Molecular interactions between extracellular components of the T‐cell receptor signaling complex , 1999, Immunological reviews.

[16]  P. Cresswell,et al.  Mechanisms of MHC class I--restricted antigen processing. , 1998, Annual review of immunology.

[17]  H Nagura,et al.  Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. , 2001, Cancer research.

[18]  R. Agarwal,et al.  Ovarian cancer: strategies for overcoming resistance to chemotherapy , 2003, Nature Reviews Cancer.

[19]  S Ferrone,et al.  HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. , 1999, Molecular medicine today.

[20]  U. G. Dailey.  Cancer,Facts and Figures about. , 2022, Journal of the National Medical Association.

[21]  J. Whelan,et al.  Striking paucity of HLA-A, B, C and beta 2-microglobulin on human neuroblastoma cell lines. , 1983, Journal of immunology.

[22]  A. Marrogi,et al.  Study of tumor infiltrating lymphocytes and transforming growth factor‐β as prognostic factors in breast carcinoma , 1997, International journal of cancer.

[23]  S. Ferrone,et al.  A method to generate antigen-specific mAb capable of staining formalin-fixed, paraffin-embedded tissue sections. , 2005, Journal of immunological methods.

[24]  J. Blattman,et al.  Cancer Immunotherapy: A Treatment for the Masses , 2004, Science.

[25]  R. Rezzani,et al.  HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  F. Dammacco,et al.  β2-Microglobulin-Free HLA Class I Heavy Chain Epitope Mimicry by Monoclonal Antibody HC-10-Specific Peptide1 , 2003, The Journal of Immunology.

[27]  S. Ferrone,et al.  Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications , 2005, Oncogene.

[28]  H Nagura,et al.  CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. , 1998, Cancer research.

[29]  S. Ferrone,et al.  Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival? , 2006, Cancer Immunology, Immunotherapy.

[30]  R. Ferris,et al.  Role of Antigen-Processing Machinery in the In Vitro Resistance of Squamous Cell Carcinoma of the Head and Neck Cells to Recognition by CTL1 , 2006, The Journal of Immunology.

[31]  Dominique Charron,et al.  HLA : genetic diversity of HLA functional and medical implication , 1997 .

[32]  U. Ritz,et al.  Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  H. Ploegh,et al.  Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. , 1986, Journal of immunology.

[34]  B. Seliger,et al.  MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma , 2004, International journal of cancer.

[35]  J. Schlom,et al.  Cancer vaccines: preclinical studies and novel strategies. , 2006, Advances in cancer research.

[36]  D. Hicklin,et al.  Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. , 1999, The American journal of pathology.

[37]  B. Seliger,et al.  Defects in the Human Leukocyte Antigen Class I Antigen Processing Machinery in Head and Neck Squamous Cell Carcinoma: Association with Clinical Outcome , 2005, Clinical Cancer Research.